BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 16400334)

  • 1. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
    Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
    Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation.
    Egerer G; Goldschmidt H; Hensel M; Harter C; Schneeweiss A; Ehrhard I; Bastert G; Ho AD
    Bone Marrow Transplant; 2002 Oct; 30(7):427-31. PubMed ID: 12368954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
    Böhme A; Shah PM; Stille W; Hoelzer D
    Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
    Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
    Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.
    Reich G; Cornely OA; Sandherr M; Kubin T; Krause S; Einsele H; Thiel E; Bellaire T; Dörken B; Maschmeyer G
    Br J Haematol; 2005 Jul; 130(2):265-70. PubMed ID: 16029455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
    Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T;
    Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
    Sato T; Kobayashi R; Yasuda K; Kaneda M; Iguchi A; Kobayashi K
    Pediatr Blood Cancer; 2008 Dec; 51(6):774-7. PubMed ID: 18661495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
    Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
    J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
    Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
    J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
    Roy S; Higareda I; Angel-Muller E; Ismail M; Hague C; Adeyi B; Woods GL; Teppler H;
    Infect Dis Obstet Gynecol; 2003; 11(1):27-37. PubMed ID: 12839630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
    Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
    Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies.
    Fernández-Avilés F; Carreras E; Urbano-Ispizua A; Rovira M; Martínez C; Gaya A; Granell M; Ramiro L; Gallego C; Hernando A; Segura S; García L; González M; Valverde M; Montserrat E
    J Clin Oncol; 2006 Oct; 24(30):4855-61. PubMed ID: 17001069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Piperacilline/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'étude des Aplasies Fébriles].
    Marie JP; Vekhoff A; Cony-Makhoul P; Fière D; Guy H; Herbrecht R; Milpied N; Pico JL; Plantier I
    Presse Med; 1995 Feb; 24(8):397-401. PubMed ID: 7899419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.